ClinicalTrials.gg
CompletedNCT05908838Updated Jun 18, 2023

Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer

An Early Phase 1 interventional study of Modified Banxia Xiexin Decoction and combination chemotherapy with Placebo granules in Gastric Cancer (Diagnosis), sponsored by ShuGuang Hospital. Completed. Open to participants aged 17 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by ShuGuang Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 years 5 months after the study started (first participant enrolled Jan 2017, registered Jun 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
17 Years to 75 Years
Sex
All
01

Study summary

Research purpose To elucidate the effect mechanism and clinical effective of Modified Banxia Xiexin Decoction in the prevention and treatment of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of Modified Banxia Xiexin Decoction's treatment on gastric cancer

Read the detailed description

Modified Banxia Xiexin Decoction treatment and mechanism on Gastric Cancer. Main Responsibility Person: Mingyu Sun research center#Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Trial Objective#Observe the clinical efficacy and mechanism of Modified Banxia Xiexin Decoction in the treatment gastric cancer Therapeutic Schedule#In this study, 146patients with gastric cancer who received chemotherapy in the Department of Gastrointestinal Surgery and Oncology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine were recruited and divided into groups according to random number table method, namely, 73 patients in the Modified Banxia Xiexin Decoction combined chemotherapy group and 73 patients in the Placebo granules combined chemotherapy group.Modified Banxia Xiexin Decoction group was treated with 18 weeks of Chinese patent medicine Modified Banxia Xiexin Decoction at the same time of chemotherapy. The Overall survival, Progression-free survival, Solid tumor efficacy, TCM syndrome score, quality of life score, Tumor markers, Immune function and adverse reactions of the two groups before and 18 weeks after treatment were observed and compared. Elucidate the possible mechanism of action of Modified Banxia Xiexin Decoction in the treatment of gastric cancer patients.

02

Conditions studied

  • Gastric Cancer (Diagnosis)

Keywords

  • Modified Banxia Xiexin Decoction
  • Gastric Cancer
  • Clinical Efficacy
  • Randomized clinical trial
  • Mechanism
03

In context

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

This study's enrollment of 146 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

ShuGuang Hospital is the lead sponsor of 18 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with stage IV gastric cancer with a clear cytological or pathological diagnosis.
  2. The patient is willing to receive palliative chemotherapy (more than 6 months between the first treatment or the last chemotherapy).
  3. At least one revealed by imaging (PET-CT, CT, MRI, bone scan, x-ray).
  4. Expected survival of ≥ 6 months.
  5. It is consistent with the diagnosis of spleen qi deficiency and cold-heat mismatch in TCM.
  6. Age 18 to 75 years with a physical condition score of (0-1).
  7. The blood count is normal, heart, liver and kidney functions are not abnormal, and the is basically normal.
  8. Patients have good compliance, are able to understand the study and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of severe cardiovascular, urinary, hematological and digestive system diseases.
  2. Pregnant or breastfeeding women with uncontrollable mental disorders.
  3. With gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia.
  4. Complications of serious infectious diseases such as active tuberculosis.
  5. Those with to chemotherapy or frequent vomiting.
  6. Poor compliance.
  7. Patients who have used other trial drugs or in other clinical trials in the past month.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Active comparator
    combination chemotherapy with Modified Banxia Xiexin Decoction

    146 patients with gastric cancer were randomly divided into a treatment group of 73 cases and a control group of 73 cases. The treatment group received combination chemotherapy with Modified Banxia Xiexin Decoction

    Drug: Modified Banxia Xiexin Decoction

  • Placebo comparator
    combination chemotherapy with Placebo granules

    The control group received combination chemotherapy with Placebo granules.

    Drug: combination chemotherapy with Placebo granules

Interventions

  • DrugModified Banxia Xiexin Decoction

    The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.

  • Drugcombination chemotherapy with Placebo granules

    combination chemotherapy with Placebo granules

06

What researchers measure

Primary outcomes

  1. Overall survival

    To observe the effects of treatment group and control group on OS in patients with advanced gastric cancer, and evaluate whether there is statistical difference in OS between the two groups.From date of randomization until the date of death from any cause, whichever came first, assessed up to 18 months.

    Time frame: the patients' were included into the clinical trials and up to 18 weeks treatment

Secondary outcomes

  1. Progression-free survival

    The time between the first treatment and tumor progression or death.From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months. To observe the effects of treatment group and control group on PFS in patients with advanced gastric cancer, and evaluate whether there is a statistical difference in PFS between the two groups.

    Time frame: the patients' were included into the clinical trials and up to 18 weeks treatment

  2. EORTC QLQ-C30

    The quality of life score is based on the EuroPean organization for Research and Treatment (EORTC) Quality of Life Scale (QLQ-C30 v3.0), which records changes in quality of life before and after treatment and compares them. Linear transformation of statistical results was performed to obtain standardized scores (0\~100 points), so that scores in various fields could be compared with each other, and the problem of reverse entries could be solved at the same time. The higher the score of symptom field obtained by each subscale, the worse the quality of life condition. The higher the scores in the areas of function and general health, the better the patient's quality of life. Analyze whether there was a statistical difference between the two groups.

    Time frame: the patients' were included into the clinical trials and up to 18 weeks treatment

  3. Clinical symptoms

    According to the scoring criteria of the Guidelines for Clinical Research of New Chinese Medicines (2002), the symptoms of patients after treatment were determined. The improvement of patients' overall symptoms was evaluated by Nimodipine method, and the efficacy index after treatment = (total score before treatment - total score after treatment)/total score before treatment \*100%.

    Time frame: the patients' were included into the clinical trials and up to 18 weeks treatment

  4. Tumor markers

    Detect the biomarkers (CA72-4, CEA, CA19-9, CA242, CA50, CA125) of two groups of patients before and after treatment to determine whether there is a statistical difference between the two groups before and after treatment.

    Time frame: the patients' were included into the clinical trials and up to 18 weeks treatment

  5. Immune function

    T cell subsets of the two groups to determine whether there was a statistical difference between the two groups before and after treatment.

    Time frame: the patients' were included into the clinical trials and up to 18 weeks treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Dec 2022, 71 months.

Of 75 non-industry phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 31. This study's 71 months is above that.

Counting every sponsor, half of 242 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jun 18, 2023
StartActual
Jan 1, 2017
Primary completionActual
Dec 1, 2022
CompletionActual
Dec 2, 2022
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05908838
Lead sponsor
ShuGuang Hospital
Responsible party
Mingyu Sun (Clinical Professor, ShuGuang Hospital) — Principal investigator
First posted
Jun 18, 2023
Start date
Jan 1, 2017
Primary completion
Dec 1, 2022
Completion
Dec 2, 2022
Last update
Jun 18, 2023

Study contacts

Mingyu Sun, doctor
principal investigator · Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion